The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Heart Journal

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ahj.2011.08.012PMID 22093195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.

  2010cited by this paper
• Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital.

  2010cited by this paper
• Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

  2009cited by this paper
• Issues to consider in the pharmaceutical development of a cardiovascular polypill

  2009cited by this paper
• Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population

  2009cited by this paper
• European cardiovascular disease statistics

  2008cited by this paper
• Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction

  2008cited by this paper
• Public policy and the challenge of chronic noncommunicable diseases

  2007cited by this paper
• Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.

  2007cited by this paper
• The preventive polypill--much promise, insufficient evidence.

  2007cited by this paper
• The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.

  2007cited by this paper
• Fixed-dose combinations improve medication compliance: a meta-analysis.

  2007cited by this paper
• A polypill for secondary prevention: time to move from intellectual debate to action

  2007cited by this paper
• Benefits, challenges, and registerability of the polypill.

  2006cited by this paper
• [Reduction in acute myocardial infarction mortality over a five-year period].

  2006cited by this paper
• Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

  2006cited by this paper
• Reducción de la mortalidad por infarto agudo de miocardio en un período de 5 años

  2006cited by this paper
• WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).

  2005cited by this paper
• Polypill holds promise for people with chronic disease.

  2005cited by this paper
• Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes

  2004cited by this paper
• Priority medicines for Europe and the world

  2004cited by this paper
• Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research

  2004cited by this paper
• A strategy to reduce cardiovascular disease by more than 80%

  2003cited by this paper
• Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action

  2002cited by this paper
• Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence

  1986cited by this paper
• A simple approximation for calculating sample sizes for comparing independent proportions.

  1980cited by this paper

• Physicochemical and dissolution properties of ezetimibe–aspirin binary system in development of fixed-dose combinations

  2020cites this paper
• Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

  2017cites this paper
• Foreword.

  2017cites this paper
• Polypharmacy in Older Adults With Hypertension: A Comprehensive Review

  2016cites this paper
• The So-Called Polypill: The Solution or the Problem?

  2016cites this paper
• Expert opinion: the therapeutic challenges faced by statin intolerance

  2016cites this paper
• Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products

  2016cites this paper
• CNIC: Achieving Research Excellence Through Collaboration El CNIC: investigacion de excelencia basada en la colaboracion

  2016cites this paper
• Innovación en la prevención cardiovascular: la polipíldora

  2016cites this paper
• Polypill: quo vadis?

  2016cites this paper
• Effectiveness and safety of a cardiovascular polypill containing aspirin

  2015cites this paper
• The Past, Present, and Future of Drug Development and Treatment in Sleep Disorders

  2015cites this paper
• Patients’ and Providers’ Perspectives of a Polypill Strategy to Improve Cardiovascular Prevention in Australian Primary Health Care: A Qualitative Study Set Within a Pragmatic Randomized, Controlled Trial

  2015cites this paper
• Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease

  2015cites this paper
• A polypill strategy to improve adherence: results from the FOCUS project.

  2014cites this paper
• A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.

  2014cites this paper
• Global Perspective on Acute Coronary Syndrome: A Burden on the Young and Poor

  2014cites this paper
• The concept of the polypill in the prevention of cardiovascular disease.

  2014cites this paper
• Combination therapy in dyslipidemia: where are we now?

  2014cites this paper
• Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care

  2014cites this paper
• Top 10 cardiovascular therapies and interventions for the next decade

  2014cites this paper
• Evolution of the polypill concept and ongoing clinical trials.

  2014cites this paper
• Das Risikofaktorenkonzept in der kardiologischen Rehabilitation: eine ethnographische Studie

  2014cites this paper
• Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care

  2014cites this paper
• Fixed-dose combination therapy for the prevention of cardiovascular disease.

  2014cites this paper
• Risk factor control for coronary artery disease secondary prevention in large randomized trials.

  2013cites this paper
• Prevention: Polypills for cardiovascular prevention: a step forward?

  2013cites this paper
• Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.

  2013cites this paper
• Impact of compliance with antihypertensive and lipid-lowering treatment on cardiovascular risk Benefits of fixed-dose combinations

  2013cites this paper
• Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement

  2013cites this paper
• Reducing residual risk in secondary prevention of cardiovascular disease.

  2012cites this paper
• Reducing Residual Risk in Secondary Prevention of CVD

  2012cites this paper
• Polypill (fixed-dose combination) in the prevention of cardiovascular disease: rationale and clinical data

  2012cites this paper
• Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.

  2012cites this paper
• The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials

  2012cites this paper
• CNIC: Achieving Research Excellence Through Collaboration.

  2012cites this paper
• Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.

  2012cites this paper
• La llamada polipill: ¿una solución o un problema?

  2011cites this paper